Amgen Inc Revenue Growth Rates (AMGN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amgen Inc   (NASDAQ: AMGN)
 

AMGN's Revenue Growth by Quarter and Year

Amgen Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AMGN/growth
https://api.csimarket.com/api/v1/companies/AMGN/fundamentals
https://api.csimarket.com/api/v1/companies/AMGN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
AMGN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10,365.00
2nd Quarter June 10,054.00
1st Quarter March 8,618.00
FY 29,037.00

AMGNs Annual Revenue
Amgen Inc 's Revenue in the fiscal year 2025 $ 36,751.00 millions
Amgen Inc 's Revenue in the fiscal year 2024 $ 33,424.00 millions
Amgen Inc 's Revenue in the fiscal year 2023 $ 28,190.00 millions
Amgen Inc 's Revenue in the fiscal year 2022 $ 26,323.00 millions
Amgen Inc 's Revenue in the fiscal year 2021 $ 25,979.00 millions




AMGN Revenue third quarter 2026 Y/Y Growth Comment
Amgen Inc achieved in the third quarter 2026, above Company average Revenue improvement of 8.45% year on year, to $ 10,365.00 millions.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 37 other companies have achieved higher Revenue growth. While Amgen Inc ' s Revenue increase of 8.45% ranks overall at the positon no. 1947 in the third quarter 2026.


AMGN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 8.45 %
2nd Quarter June 9.53 %
1st Quarter March 5.76 %
FY   -

Financial Statements
Amgen Inc 's third quarter 2026 Revenue $ 10,365.00 millions AMGN's Income Statement
Amgen Inc 's third quarter 2025 Revenue $ 9,557.00 millions Quarterly AMGN's Income Statement


AMGN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.09 %
2nd Quarter June 16.66 %
1st Quarter March -12.65 %
FY (Year on Year)   -


Back to AMGN Growth rate Comparisons >> Back to AMGN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #38
Healthcare Sector #290
Overall #1947

Revenue Y/Y Growth Statistics
High Average Low
23.98 % 6.59 % -8.44 %
 
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #38
Healthcare Sector #290
Overall #1947
Revenue Y/Y Growth Statistics
High Average Low
23.98 % 6.59 % -8.44 %
 

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Amgen Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
18.73 % 1.87 % -12.65 %
(Dec 31 2023)  


AMGN's III. Quarter Q/Q Revenue Comment
Amgen Inc achieved in the III. Quarter 2026 above company average sequential Revenue growth of 3.09%, to $ 10,365.00 millions, from $10,054.00 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Amgen Inc 's Revenue growth quarter on quarter, overall rank is 1366.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #190
Overall #1366
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #26
Healthcare Sector #190
Overall #1366
Revenue Q/Q Growth Statistics
High Average Low
18.73 % 1.87 % -12.65 %
(Dec 31 2023)  


AMGN's III. Quarter Q/Q Revenue Comment
Amgen Inc achieved in the III. Quarter 2026 above company average sequential Revenue growth of 3.09%, to $ 10,365.00 millions, from $10,054.00 millions in the second quarter.

Within Biotechnology & Pharmaceuticals industry 25 other companies have achieved higher Revenue quarter on quarter growth. While Amgen Inc 's Revenue growth quarter on quarter, overall rank is 1366.


Amgen Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 38,903.00
Y / Y Revenue Growth (TTM) 8.15 %
Year on Year Revenue Growth Overall Ranking # 1649
Seqeuential Revenue Change (TTM) 2.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 1649


Cumulative Revenue growth Comment
Assuming the Amgen Inc 's fiscal year would have ended in Sep 30 2026, Amgen Inc would have reprted above average annual Revenue improvement of 8.15% year on year, of $ 38,903 millions.
This marks a slow-down of the companys growth trends and from the 9.1% growth in Jun 30 2026.

In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1649, from total ranking in previous quarter at 1722.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 242
Overall # 1449

Revenue TTM Y/Y Growth Statistics
High Average Low
21.25 %
 6.21 %
-2.75 %
(Sep 30 2024)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 333
S&P 500 # 2322
Cumulative Revenue growth Comment
Assuming the Amgen Inc 's fiscal year would have ended in Sep 30 2026, Amgen Inc would have reprted above average annual Revenue improvement of 8.15% year on year, of $ 38,903 millions.
This marks a slow-down of the companys growth trends and from the 9.1% growth in Jun 30 2026.

In the Healthcare sector 241 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 1649, from total ranking in previous quarter at 1722.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 32
Healthcare Sector # 242
Overall # 1449

Revenue TTM Y/Y Growth Statistics
High Average Low
21.25 %
6.21 %
-2.75 %
(Sep 30 2024)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 39
Sector # 333
S&P 500 # 2322




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMGN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions
Aurinia Pharmaceuticals Inc 13.93%$ 13.926 millions
Indivior Pharmaceuticals Inc 13.74%$ 13.738 millions
Cryoport inc 13.54%$ 13.535 millions
Neuronetics Inc 13.35%$ 13.350 millions
Royalty Pharma Plc13.26%$ 13.263 millions
Evolus Inc 13.23%$ 13.235 millions
Privia Health Group Inc 13.19%$ 13.187 millions
Biocryst Pharmaceuticals Inc 13.11%$ 13.110 millions
U S Physical Therapy Inc12.90%$ 12.898 millions
Maravai Lifesciences Holdings Inc 12.78%$ 12.781 millions
Alphatec Holdings Inc 12.67%$ 12.670 millions
Harmony Biosciences Holdings inc 12.61%$ 12.609 millions
Medicinova Inc 12.35%$ 12.355 millions
Bionano Genomics Inc 12.34%$ 12.339 millions
Viemed Healthcare Inc 12.18%$ 12.180 millions
Ufp Technologies Inc 12.15%$ 12.154 millions
Innovage Holding Corp 12.14%$ 12.135 millions
Vertex Pharmaceuticals Inc11.85%$ 11.845 millions
Sanara Medtech Inc 11.67%$ 11.668 millions
Lemaitre Vascular Inc 11.51%$ 11.508 millions
Pacs Group Inc 11.45%$ 11.454 millions


About Amgen Inc Revenue Growth Rates (AMGN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Amgen Inc (CIK 318154).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000318154-26-000155
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Amgen Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.